Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: phase III randomised placebo controlled trial (MIR)

Overview of attention for article published in British Medical Journal, October 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

So far, Altmetric has seen 4 Google+ posts from 3 users.

“There is no evidence of a clinically important benefit for mirtazapine in addition to an SSRI or SNRI... “There is no evidence…

Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: phase III randomised placebo controlled…

Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: phase III randomised placebo controlled…

Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: phase III randomised placebo controlled…

This page shows the most recent Google+ posts that mention this research output. Click here to find out how to access more activity.